tirzepatide vs semaglutide efficacy weight loss of versus in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial | Diabetologia Tirzepatide vs Semaglutide Safety: What

Three sides of one practice One team

Obesity SURMOUNT-1 Trial In adults with obesity (without diabetes): Tirzepatide (15 mg) : 20.9% average body weight reduction over 72 weeks Semaglutide (2.4 mg) (based on STEP trials): ~14.9% average reduction STEP 5 Long-Term Results Semaglutide also demonstrated durable effects: At 104 weeks, patients maintained ~15% weight loss on semaglutide 2.4 mg (STEP 5) SELECT Trial Cardiovascular Benefit Semaglutide significantly reduced major adverse cardiovascular events by 20% in people with obesity and pre-existing heart diseaseindicating benefit beyond weight loss

This is why many people find that a comprehensive approachcombining glutathione with liver-supporting herbsyields the best results

37 King-BatoonA.LeszczynskaJ

The drugs reduce acid production in the stomach, but acid is needed to release B-12 from foods, so deficiency can occur

Weight reduction with GLP-1 analogues Doctors also prescribe GLP-1 receptor agonists for patients with type 2 diabetes who are unable to lose weight by conventional means